Patients with medically inoperable stage I/IIA non-small cell lung cancer (NSCLC) who have not received prior anticancer therapy for lung cancer, may qualify for a clinical trial investigating if the combination of pembrolizumab (MK-3475) and Stereotactic Body Radiation Therapy (SBRT) may help stop or slow a relapse of NSCLC compared to SBRT alone.
.jpg?lang=en-US&ext=.jpg)
